Key terms
About GRFS
Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest GRFS news
Apr 05
3:49pm ET
Grifols price target lowered to EUR 13 from EUR 18 at Barclays
Apr 04
6:22pm ET
Grifols says all liabilitites disclosed in audited financial statements
Apr 04
12:24pm ET
Grifols simplifies financial presentation, limits non-recurring items
Apr 04
5:57am ET
Grifols’ Procleix ArboPlex Assay receives CE Mark
Mar 21
3:03pm ET
Grifols says CNMV validates financial statements, indebtedness of Grifols
Mar 12
1:36pm ET
Grifols downgraded to Sell at Deutsche Bank on ‘problem’ of cash flow guidance
Mar 12
1:28pm ET
Grifols downgraded to Sell from Hold at Deutsche Bank
Mar 08
12:48pm ET
Grifols rallies 20% afer KPMG signs off on 2023 financials
Mar 06
5:36am ET
Grifols falls after Gotham City questions ethics in new short report
Mar 01
5:58am ET
Citi, like many investors, confused by Grifols cash flow comments
Feb 29
12:21pm ET
Grifols sees ‘zero’ cash flow this year, Bloomberg reports
Feb 29
12:16pm ET
Grifols sees FY24 revenue growth of 7% at cc
Feb 29
12:15pm ET
Grifols reports FY23 revenue EUR 6.59B, up 11% in constant currency
Feb 23
1:56pm ET
Grifols price target raised to EUR 19.40 from EUR 18.60 at Berenberg
Feb 15
8:40pm ET
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Travere Therapeutics (TVTX) and Grifols SA (GRFS)
Feb 14
5:19am ET
Grifols announces FC from Biotest met primary endpoint
Feb 07
8:40pm ET
Analysts Offer Insights on Healthcare Companies: Demant (OtherWILLF) and Grifols SA (GRFS)
Feb 05
11:51am ET
Grifols names Nacho Abia CEO, transitions for CCO, COO
Jan 26
1:04pm ET
Grifols files lawsuit against Gotham City Research, seeks monetary relief
Jan 23
8:45pm ET
Kepler Capital Reaffirms Their Buy Rating on Grifols SA (GRFS)
Jan 17
1:22pm ET
ECB asking banks on Grifols exposure after short report, Reuters reports
Jan 17
5:25am ET
Grifols downgraded to Underperform from Outperform at Oddo BHF
Jan 16
8:45pm ET
Kepler Capital Sticks to Its Buy Rating for Grifols SA (GRFS)
Jan 11
8:40pm ET
Analysts Are Bullish on These Healthcare Stocks: Nyxoah (NYXH), Grifols SA (GRFS)
Jan 11
8:43am ET
Grifols says Gotham City ‘repurposing old information out of pure self-interest’
Jan 10
9:40am ET
Grifols up 6% to $9.26 after further responding to short report
Jan 10
9:40am ET
Grifols adds to Gotham City response, will initiate legal action
Jan 10
9:39am ET
Gotham City owner reduced short position in Grifols to 0.06%, Bloomberg reports
Jan 09
9:56am ET
Grifols issues response to Gotham City Research report
Jan 09
6:25am ET
Grifols’ leverage higher than reported, short-seller Gotham City says
Yesterday
3:00am ET
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Grifols, S.A. and Encourages Investors with Losses to Contact the Firm
Apr 08
7:00pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Grifols, S.A. and Encourages Investors with Losses to Contact the Firm
Mar 29
11:33am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Grifols S.A. - GRFS
Mar 21
1:29pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Grifols S.A. - GRFS
Mar 14
8:35am ET
Grifols S.A. (GRFS - ADR ADR Class B) Shares Decline Again After Gotham City Research Issues Another Critical Report - Hagens Berman
Mar 13
9:49am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Grifols S.A. - GRFS
Mar 11
1:06pm ET
GRFS Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Grifols S.A. (GRFS) Investors to Contact the Firm
GRFS Financials
Key terms
Ad Feedback
GRFS Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
GRFS Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
